European Authorities Recommended Additional Approval of Bristol-Myers Squibb Product Onureg® for AML
Bristol-Myers Squibb (BMY): The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Onureg® (azacitidine tablets; CC-486) as maintenance therapy in adult patients with acute myeloid leukemia (AML).
The approval is for the AML . . .
This content is for paid subscribers.
Today’s Highlights April 23, 2021